Rapid Readouts

Dr Worden reviews and discusses real-world data of lenvatinib monotherapy in patients with radioiodine-refractory differentiated thyroid cancer.

Dr Cabanillas reviews updated data that was recently presented at the American Thyroid Association conference on the use of larotrectinib in patients with advanced TRK fusion positive thyroid cancer.

Dr Sara M Tolaney reviews data from the APHINITY trial regarding the pertuzumab plus trastuzumab and chemotherapy treatment regimen for patients with HER2+ breast cancer.

Dr Oh reviews data assessing the impact of pacritinib on anemia in patients from the PERSIST-2 trial. Funding supported by CTI BioPharma. Content independently developed by OncLive.

Dr. Hope Rugo reviews updates to data from the TROPiCS-02 trial that were recently presented at ESMO Congress 2022 and speaks to clinical implications of these data.

Dr Cairo reviews results from a real-world observational study comparing the incidence of tumor lysis syndrome (TLS)-associated fatalities between rasburicase monotherapy and allopurinol monotherapy.

Dr Hubbard reviews patient reported outcomes from the MOUNTAINEER trial, which evaluated the combination of tucatinib plus trastuzumab in patients with HER2-positive metastatic colorectal cancer.

Dr. El-Khoueiry evaluates the efficacy and safety of camrelizumab in combination with rivoceranib for the treatment of unresecetable hepatocellular carcinoma in the front-line setting.

Dr Finn reviews the results from the Leap-002 study which evaluates the use of lenvatinib with pembrolizumab in the front-line setting for patients with advanced hepatocellular carcinoma.

Dr Domenica Lorusso reviews data updates from KEYNOTE-775 that were recently presented at the European Society for Medical Oncology (ESMO) Congress 2022.

Dr. Tanios Bekaii-Saab discusses the results of a systematic review/meta-analysis intended to assess the impact of EGFR-targeted therapies on clinical outcomes in patients with HER2-positive metastatic colorectal cancer.

Dr Solange Peters reviews data from POSEIDON on combination durvalumab, tremelimumab, and chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC) that were recently presented at the 2022 World Conference on Lung Cancer.

Dr. Nicholas Short reviews updates to data on combination ponatinib and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that were recently presented at the 2022 European Hematology Association (EHA) Congress.

Dr Tanios Bekaii-Saab reviews data from the MOUNTAINEER trial on combination tucatinib/trastuzumab in patients with HER2-positive metastatic colorectal cancer.

Dr Levy presents updated safety and efficacy results on larotrectinib in patients with TRK fusion-positive lung cancer.

Dr Benjamin Levy reviews long-term, pooled safety and efficacy data on larotrectinib in patients with TRK fusion-positive cancers.

Dr Nooka reviews the patient reported outcomes from the MajesTEC-1 trial in patients with relapsed/refractory multiple myeloma.

Dr. Pau Montesinos reviews the efficacy of ivosidenib and azacitidine in reducing transfusions and improving blood counts in patients with newly diagnosed acute myeloid leukemia.

Dr Elisabet Manasanch reviews updated data from the IKEMA study in patients with relapsed multiple myeloma.

Dr. Tycel Phillips reviews pivotal dose-expansion results from the EPCORE NHL-1 trial on epcoritamab in patients with relapsed or refractory large B-cell lymphoma (LBCL).

Dr Vinod Ravi talks about nab-SIROLIMUS and reviews the data from the AMPECT trial.

Dr. Kim reviews the RASER study and discusses how radiation segmentectomy could be a potential treatment option for patients with unresectable hepatocellular carcinoma.

Dr. Waguespack reviews efficacy and safety data for larotrectinib in patients with TRK fusion-positive thyroid carcinoma.

Dr. Pal analyzes and reviews the results from long term follow-up data on PFS from the TIVO-3 trial.

Expert urologist Benjamin Lowentritt, MD, reviews advanced prostate cancer data from the SPARTAN and TITAN studies comparing patient-reported outcomes to changes in PSA.

Dr. Natalie Callander reviews data from the DREAMM-5 study presented at ASH 2021, which assessed the safety and efficacy of belantamab mafodotin plus feladilimab in patients with relapsed/refractory multiple myeloma with disease resistance to at least 3 prior lines of therapy.

Dr. Tripathy reviews the safety and efficacy data from a phase 2 non-randomized study of tucatinib-trastuzumab-capecitabine regimen in patients with leptomeningeal metastasis.

Expert urologist Benjamin Lowentritt, MD, reviews trial data comparing PsA response achieved with apalutamide versus enzalutamide in patients with castration-sensitive prostate cancer.

Alan H. Bryce, MD, discusses the ARASENS trial, as presented at The American Society of Clinical Oncology Genitourinary Cancers Symposium in February 2022.

Sagar Lonial, MD, discusses the part 1 results of a study combining belantamab mafodotin with pomalidomide and dexamethasone when treating relapsed/refractory multiple myeloma, as presented by Suzanne Trudel, MD, at the American Society of Hematology 2021 Annual Meeting.